Congratulations to the Miska Group on their Cancer Research UK Discovery Programme Award. They will use the award to investigate the role of METTL1 in cancer protein production, oncogenic RNA structure-function modifications and screening RNA structures to identify novel therapeutic targets.
Their research aims to understand key control steps at the level of RNA, how these might be deregulated in cancer and how this might be exploited for cancer therapeutics. The focus is on RNA structures and RNA modifying enzymes. The most significant outcome of this programme is the identification of novel strategies to target RNA structures and RNA modifying enzymes as a cancer therapy.